Highlights
- Major Pathologic Response (MPR), defined as Evans grade III or IV, is achieved in approximately 11.5% of patients with pancreatic ductal adenocarcinoma (PDAC) following preoperative therapy.
- Achievement of MPR is a potent independent prognostic factor, associated with a median overall survival of 71.5 months compared to 40.9 months in non-responders.
- Preliminary evidence suggests that the benefit of adjuvant chemotherapy may be attenuated in patients who achieve MPR, potentially allowing for de-escalated postoperative management.
- Predictive factors for MPR include the use of chemoradiotherapy, a preoperative treatment duration of six months or longer, and normalization of CA 19-9 levels.
Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by early systemic dissemination and a profound resistance to conventional therapies. For decades, the standard of care was primary surgery followed by adjuvant chemotherapy. However, the high rate of early recurrence and the failure of many patients to even initiate adjuvant treatment due to surgical complications led to a paradigm shift toward preoperative (neoadjuvant) therapy.
Neoadjuvant therapy (NAT) aims to eradicate micrometastatic disease, increase the rate of R0 resections, and serve as a biological litmus test to identify patients with rapidly progressive disease who would not benefit from surgery. While radiologic assessment (RECIST) is the standard for monitoring response, it often correlates poorly with the actual extent of viable tumor in PDAC due to the dense desmoplastic reaction characteristic of these tumors. Consequently, the pathologic response observed in the resected specimen has emerged as a critical metric for evaluating the efficacy of preoperative protocols. Until recently, the specific prognostic impact of a “Major Pathologic Response” (MPR) and its implications for subsequent adjuvant therapy remained insufficiently characterized in large-scale cohorts.
Key Content
Pathologic Grading and the Definition of MPR
The assessment of pathologic response in PDAC typically utilizes systems such as the College of American Pathologists (CAP) score or the Evans classification. The study by Yamane et al. utilized the Evans classification, which categorizes response based on the percentage of destroyed or degenerated tumor cells. In this framework, Evans Grade I represents <10% destruction, Grade II represents 10–90% destruction, Grade III indicates >90% destruction (with few remaining viable cells), and Grade IV denotes a complete pathologic response (no viable tumor cells).
MPR is defined as Evans Grade III or IV. This threshold is significant because it represents a profound biological sensitivity to the preoperative regimen. In the multi-institutional analysis of 739 Japanese patients, MPR was achieved in 11.5% of cases, highlighting that while profound response is possible, it remains an elusive goal for the majority of patients receiving current standard-of-care NAT.
Survival Outcomes: The Prognostic Superiority of MPR
The survival data from this large-scale retrospective study underscore the transformative impact of high-grade pathologic response. Patients achieving MPR demonstrated a median overall survival (OS) of 71.5 months, nearly double the 40.9 months observed in the non-MPR group. The difference in recurrence-free survival (RFS) was even more striking: 55.5 months for the MPR group versus only 15.2 months for the non-MPR group.
Multivariate analysis confirmed that MPR is an independent predictor of OS, carrying more prognostic weight than traditional staging factors such as lymph node status or margin involvement in the post-NAT setting. This suggests that the degree of tumor destruction is a direct reflection of both local control and the eradication of occult systemic disease.
The Adjuvant Chemotherapy Controversy
Perhaps the most provocative finding of recent research concerns the role of adjuvant chemotherapy following NAT and resection. Current clinical guidelines generally recommend adjuvant chemotherapy for all patients regardless of the NAT response, largely based on trials like PRODIGE 24 and ESPAC-4. However, the data from Yamane et al. suggest that in the specific subgroup of patients who achieve MPR, the administration of adjuvant chemotherapy did not significantly improve OS or RFS.
In the MPR subgroup, multivariate analysis failed to identify adjuvant therapy as an independent prognostic factor. This raises a critical clinical question: Does the profound response to preoperative therapy indicate that the systemic disease has already been adequately addressed, rendering further toxic chemotherapy redundant? While these retrospective results require prospective validation, they point toward a future of “response-adapted therapy” where the intensity of postoperative treatment is tailored to the pathologic response.
Predictors of Achieving MPR
Given the superior survival associated with MPR, identifying which patients are likely to achieve it—and which protocols favor it—is essential. The study identified four key predictive factors:
- Chemoradiotherapy (CRT): Patients receiving radiation in addition to chemotherapy were more likely to achieve MPR, suggesting that local dose intensification contributes to higher grades of pathologic destruction.
- Duration of NAT: A preoperative treatment duration of ≥6 months was associated with higher MPR rates, suggesting that longer exposure to systemic therapy may be necessary to maximize tumor cell kill.
- CA 19-9 Normalization: Patients whose carbohydrate antigen 19-9 levels returned to the normal range after NAT had a higher probability of MPR, serving as a reliable biochemical marker of response.
- Radiologic Response: Although radiology is imperfect in PDAC, a complete or partial response by RECIST criteria still correlated significantly with MPR.
Expert Commentary
The findings from this 739-case multi-institutional study provide a robust evidentiary basis for using MPR as a primary endpoint in clinical trials. From a biological perspective, the lack of benefit from adjuvant chemotherapy in the MPR group suggests that these patients have reached a state of “minimal residual disease” where the incremental benefit of additional cytotoxic drugs is outweighed by the toxicity or the biological resistance of any remaining dormant cells.
However, clinicians must exercise caution. The retrospective nature of the data introduces potential selection bias—healthier patients might have been more likely to receive longer NAT or tolerate adjuvant therapy. Furthermore, the Japanese cohort typically receives S-1 as a backbone of therapy, which may differ in efficacy and toxicity profile compared to the FOLFIRINOX or Gemcitabine/Nab-paclitaxel regimens more common in Western centers.
The mechanistic rationale for the success of longer NAT (≥6 months) is particularly interesting. It suggests that PDAC, with its complex microenvironment and hypoxic niches, requires sustained systemic pressure to overcome its inherent chemoresistance. The predictive model developed in this study offers a pragmatic tool for clinicians to estimate the likelihood of MPR and could potentially be used to stratify patients in future randomized controlled trials.
Conclusion
Pathologic response is a critical indicator of treatment efficacy in resected PDAC. Achieving a Major Pathologic Response (Evans III/IV) identifies a patient population with an exceptional prognosis, with median survival exceeding five years. The observation that adjuvant chemotherapy may not provide additional benefit to these “super-responders” represents a potential landmark in the movement toward de-escalating therapy for highly responsive disease. Future prospective trials, such as those utilizing circulating tumor DNA (ctDNA) alongside pathologic grading, will be necessary to definitively establish MPR as a surrogate for omitting or modifying adjuvant treatment. For now, MPR should be documented in every pathology report to guide clinician-patient discussions regarding long-term prognosis and postoperative care.
References
- Yamane K, Nagai K, Anazawa T, et al. Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective Study of 739 Cases. Annals of Surgery. 2026; PMID: 41843644.
- Versteijne E, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-1773. PMID: 32105488.
- Conroy T, et al. Folfirinox or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. PMID: 30575490.
- Evans DB, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335-9. PMID: 1444998.